During rehabilitation sessions in May, the patient successfully identified individual letters and words using the two-millimeter square chip. The device functions as artificial photoreceptors, receiving visual data from camera-equipped glasses to stimulate the optic nerve. While the current field of view is limited to a high-contrast, black-and-white central patch, the company aims to scale the technology to achieve near-native visual acuity within five years.
Science Corporation implants vision-restoring chip in Stargardt patient
A patient with Stargardt disease, an incurable condition causing gradual blindness, has received the PRIMA retinal implant in a clinical trial at Sydney Eye Hospital. The procedure marks a significant milestone for Science Corporation, the neurotechnology firm founded by former Neuralink president Max Hodak to advance brain-computer interface applications.
Science Corporation positions this retinal prosthesis as a practical bridge toward its broader mission: mapping the neural mechanisms of the mind. Unlike Neuralink’s approach of inserting electrodes directly into brain tissue, the company’s separate BCI sensor is designed to rest on the brain's surface. Hodak views these medical applications as the foundation for future health-span extension, anticipating that brain-computer interfaces will eventually become a standard intervention for age-related neurological decline.
Comments (0)
No comments yet. Be the first!